VRC-HIVMAB060-00-AB (VRC01)

BIOLOGICAL3 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

HIVHIV AntibodiesMonoclonal Antibody, HumanNeutralizing AntibodyPrevention of HIV Infection

Phase 1

VRC-HIVMAB060-00-AB (VRC01) in People With Chronic HIV Infection Undergoing Analytical Treatment Interruption

CompletedNCT02471326

National Institute of Allergy and Infectious Diseases (NIAID)HIV

Start: 2015-07-13End: 2017-04-07Updated: 2017-10-31

Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB080-00-AB (VRC01LS), With Broad HIV-1 Neutralizing Activity, Administered Intravenously or Subcutaneously to Healthy Adults

CompletedNCT02599896

National Institute of Allergy and Infectious Diseases (NIAID)HIV Antibodies, Monoclonal Antibody, Human, Neutralizing Antibody +1

Start: 2015-11-16End: 2018-07-25Updated: 2019-12-17

Combination Therapy With VRC01 and 10-1074 in HIV-Infected Individuals Undergoing Sequential Treatment Interruptions

TerminatedNCT03831945

National Institute of Allergy and Infectious Diseases (NIAID)HIV

Start: 2019-04-04End: 2020-12-08Updated: 2021-10-12

Related Papers

Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults

PLoS Medicine2018-01-24249 citations

Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption

New England Journal of Medicine2016-11-09463 citations